Library
LL-37
ImmuneAlso known as human cathelicidin, hCAP18 fragment
The body's own 37-amino-acid antimicrobial peptide.
Read this first
Injecting LL-37 means administering the exact molecule used to induce rosacea in animal models. Both registered interventional trials chose local delivery, most likely because systemic cationic antimicrobial peptides risk haemolysis.
How it works
Cationic and amphipathic, it disrupts microbial membranes directly. It is also an immune signalling molecule, driving chemotaxis and TLR2 signalling.
SubcutaneousTopical
In the body
No plasma curve is shown for this compound.
Unknown. No pharmacokinetic data for administered LL-37 was found.
Doses
250 mcgweekly, injected into the lesionEarly human data
The melanoma trial that used this dose enrolled four patients. That is the entire interventional injection experience.
Vial sizes
5 mg10 mg
Side effects
- Essentially uncharacterised in humans.
Cautions
- Rosacea, psoriasis, lupus or other inflammatory skin disease. This is the strongest contraindication of any compound in this library: intradermal LL-37 injection is the standard method for inducing rosacea-like lesions in mice, and LL-37 acts as an autoantigen in lupus.
Status
Not approved. Not compoundable. Not listed by WADA.
Reference information for personal record-keeping. Not medical advice, and not a recommendation to use any of these compounds.